If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How does tirzepatide compare with once-weekly semaglutide 2 mg?
Although there are no head-to-head clinical trials comparing tirzepatide with semaglutide 2 mg, an indirect treatment comparison showed tirzepatide had significant HbA1c and weight change from baseline for the tirzepatide 10 and 15 mg doses.
See important safety information, including boxed warning, in the attached prescribing information.
Semaglutide Comparison
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
SURPASS-2 compared tirzepatide with once-weekly semaglutide 1 mg, the highest approved dose of semaglutide available at the time.2,3
Eli Lilly and Company has not conducted clinical studies comparing tirzepatide with once-weekly semaglutide 2 mg.3
Indirect Treatment Comparison
An adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 2 mg was assessed in patients with T2D using aggregate data from the SURPASS-2 phase 3 clinical trial and from the SUSTAIN FORTE phase 3 clinical trial metformin-only population.4
Refined data from SURPASS-2 were included that took into consideration the more restrictive glycated hemoglobin (HbA1c) inclusion criterion of the SUSTAIN FORTE trial. From the SUSTAIN FORTE trial, the metformin-only population for change from baseline in HbA1c and body weight at week 40 was used as the primary analysis.4
Adjust Baseline Demographics
The baseline age, HbA1c, and fasting plasma glucose of the SURPASS-2 refined population for the semaglutide 1 mg treatment arm were very similar to the SUSTAIN FORTE full population. Baseline body weight–related characteristics were slightly higher in the SUSTAIN FORTE full population versus the SURPASS-2 refined population.4
HbA1c Results
Using the aITC, tirzepatide significantly reduced HbA1c at week 40 from baseline more than semaglutide 2 mg with an estimated treatment difference (ETD) of
- -0.36%; 95% CI, -0.63 to -0.09; p=.008 for tirzepatide 10 mg, and
- -0.4%; 95% CI, -0.67 to -0.13; p=.003 for tirzepatide 15 mg.4
There were no significant differences between tirzepatide 5 mg and semaglutide 2 mg (ETD of 0.07%; 95% CI, -0.2 to 0.34; p=0.606).4
Weight Results
Using the aITC, tirzepatide significantly reduced body weight at week 40 from baseline more than semaglutide 2 mg with an ETD of
- -3.15kg; 95% CI, -4.84 to -1.46; p<.001 for tirzepatide 10 mg, and
- -5.15 kg; 95% CI, -6.85 to -3.45; p<.001 for tirzepatide 15 mg.4
There were no significant differences between tirzepatide 5 mg and semaglutide 2 mg on ETD of -0.65 kg; 95% CI, -2.35 to 1.05; p=0.453.4
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
4Vadher K, Patel H, Mody R, et al. Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison. Diabetes Obes Metab. Published online May 19, 2022. https://doi.org/10.1111/dom.14775
Date of Last Review: May 23, 2022